7Baggers

Anebulo Pharmaceuticals Inc
(NASDAQ:ANEB) 

ANEB stock logo

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction.

Founded: 2020
Founder: Joseph F. Lawler 
CEO: Daniel Schneeberger  
Sector:
Industry:
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-03-31 2023-12-31 2023-09-30 2022-06-30 2021-06-30 2021-03-31 
                
      research and development
    		1,164,737 809,991 1,126,223 638,324 1,220,535 1,314,859 748,339 1,062,672 1,270,220  1,806,692 273,038 
      general and administrative
    		1,455,173 1,450,269 1,204,661 1,253,998 1,367,616 1,097,265 915,912 1,697,787 1,273,458  678,013 279,093 
      total operating expenses
    		2,619,910 2,260,260 2,330,884 1,892,322 2,588,151 2,412,124 1,664,251 2,760,459 2,543,678  2,484,705 552,131 
      income from operations
    		-2,619,910 -2,260,260 -2,330,884 -1,892,322 -2,588,151 -2,412,124 -1,664,251 -2,760,459 -2,543,678    
      yoy
    		1.23% -6.30% 40.06% -31.45% 1.75%        
      qoq
    		15.91% -3.03% 23.18% -26.89% 7.30% 44.94% -39.71% 8.52%     
      other expenses:
    		            
      interest expense
    		17,439 17,439 17,439 245,182 59,696 59,697 59,696 31,838    3,701 
      interest income
    		-85,410 -109,616 -122,583 -102,257 -7,067 -26,006 -68,084 -75,522 -55,198    
      grant income
    		-552,576 -9,825 -81,343 -359,606 -177,703 -245,362       
      other
    		34 96 431 528 -47 283 -2,321 594 -7,657    
      other income
    		-620,513 -101,906 -186,056 -216,153 -125,121 -211,388 -10,709      
      net income
    		-1,999,397 -2,158,354 -2,144,828 -1,676,169 -2,463,030 -2,200,736 -1,653,542 -2,717,369 -2,480,823  -29,111,739 -555,832 
      yoy
    		-18.82% -1.93% 29.71% -38.32% -0.72%  -94.32% 388.88%     
      qoq
    		-7.36% 0.63% 27.96% -31.95% 11.92% 33.09% -39.15% 9.53%   5137.51%  
      weighted-average common shares outstanding, basic and diluted
    		41,084,731 41,084,731  41,084,731  25,933,217 25,933,217  25,633,217  13,612,701 12,982,500 
      net income per share
    		-0.05 -0.05 -0.05 -0.04 -0.09 -0.08 -0.06 -0.11 -0.1  -2.09 -0.68 
      weighted average common shares outstanding, basic and diluted
    		  33,820,306  27,415,430   25,789,739     
      other expenses
    		       -43,090     
      other incomes:
    		            
      total other incomes
    		        -62,855    
      operating expenses:
    		            
      other expense:
    		            
      loss from operations before taxes
    		          -285,203.75 -555,832 
      income tax expense
    		            
      deemed dividend
    		          -2,052,098.25 -8,208,393 
      net loss attributable to common stockholders
    		          -29,111,739 -8,764,225 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 
                        
        assets
      		                  
        current assets:
      		                  
        cash and cash equivalents
      		9,041,570 10,354,773 11,627,849 13,279,901 14,998,467 1,404,211 3,094,200 5,147,139 6,644,517 8,520,578         
        grant receivable
      		56,783 9,825 73,218  30,756 245,362             
        prepaid expenses
      		175,413 170,771 261,439 528,034 366,266 312,940 413,790 223,676 171,740 527,306 422,748 267,801 532,906 601,668 1,030,960    
        total current assets
      		9,273,766 10,535,369 11,962,506 13,807,935 15,395,489 1,962,513 3,507,990 5,370,815 6,816,257          
        other assets:
      		                  
        loan commitment fees
      		148,231 165,670 183,110 200,549 445,731 505,427 565,124 624,820 684,516          
        total assets
      		9,421,997 10,701,039 12,145,616 14,008,484 15,841,220 2,467,940 4,073,114 5,995,635 7,500,773 9,047,884 11,670,151 14,432,606 16,888,256 19,815,365 15,579,431 17,248,467 18,963,871 20,500,342 
        liabilities and stockholders’ equity
      		                  
        current liabilities:
      		                  
        accounts payable
      		554,862 607,539 224,175 427,578 319,515 252,142 156,426 384,920 318,679 565,949 534,545 570,902 346,554 523,473 380,828 83,277 42,944 493,819 
        accrued expenses
      		930,784 356,282 263,513 118,454 559,284 317,083 104,157 625,401 694,877 150,611 534,256 920,183 1,025,847 174,706 131,703 2,500 7,000 113,887 
        total liabilities
      		1,485,646 963,821 487,688 546,032 878,799 569,225 260,583 1,010,321 1,013,556 716,560 1,068,801 1,491,085 1,372,401 698,179 512,531 85,777 49,944 607,706 
        commitments and contingencies
      		                  
        stockholders’ equity:
      		                  
        preferred stock, 0.001 par value...
      		                  
        common stock, 0.001 par value...
      		41,086 41,086 41,086 41,086 41,086 25,934 25,934 25,934 25,934 25,634 25,634 25,634 25,634 25,634 23,345 23,345 23,345 23,345 
        additional paid-in capital
      		85,941,523 85,742,993 85,505,349 85,165,045 84,988,845 69,477,261 69,190,341 69,013,155 68,861,516 67,988,554 67,777,757 67,622,348 67,398,711 67,173,090 60,513,258 60,286,306 60,161,052 60,066,770 
        accumulated deficit
      		-78,046,258 -76,046,861 -73,888,507 -71,743,679 -70,067,510 -67,604,480 -65,403,744 -64,053,775 -62,400,233 -59,682,864 -57,202,041 -54,706,461 -51,908,490 -48,081,538 -45,469,703 -43,146,961 -41,270,470 -40,197,479 
        total stockholders’ equity
      		7,936,351 9,737,218 11,657,928 13,462,452 14,962,421 1,898,715 3,812,531 4,985,314 6,487,217 8,331,324 10,601,350 12,941,521 15,515,855 19,117,186 15,066,900 17,162,690 18,913,927 19,892,636 
        total liabilities and stockholders’ equity
      		9,421,997 10,701,039 12,145,616 14,008,484 15,841,220 2,467,940 4,073,114 5,995,635 7,500,773 9,047,884 11,670,151 14,432,606 16,888,256 19,815,365 15,579,431 17,248,467 18,963,871 20,500,342 
        cash
      		          11,247,403 14,164,805 16,355,350 19,213,697 14,548,471 16,547,727 18,008,990 19,207,743 
        prepaid expenses and other current assets
      		               700,740 954,881 1,292,599 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2024-03-31 2023-12-31 2023-09-30 
           
          cash flows from operating activities:
        		   
          net income
        		-1,653,542 -2,717,369 -2,480,823 
          adjustments to reconcile net income to net cash from operating activities
        		   
          stock-based compensation
        		151,639 219,262 210,797 
          amortization of loan commitment fee
        		59,696   
          changes in operating assets and liabilities:
        		   
          prepaid expenses
        		-51,936 355,566 -104,558 
          accounts payable
        		66,241 -247,270 31,404 
          accrued expenses
        		-69,476 544,266 -383,645 
          net cash from operating activities
        		-1,497,378 -1,813,707 -2,726,825 
          capital expenditures
        		0 0 0 
          free cash flows
        		-1,497,378 -1,813,707 -2,726,825 
          cash flows from financing activities:
        		   
          proceeds from issuance of common stock
        		   
          payment of financing/offering costs
        		0   
          proceeds from issuance of common stock upon exercise of options
        		   
          net cash from financing activities
        		0   
          net decrease in cash
        		   
          cash, beginning of period
        		0   
          cash, end of the period
        		-1,497,378   
          noncash investing and financing activities:
        		   
          financing commitment fee funded through issuance of common stock
        		0   
          4
        		   
          net increase in cash
        		   
          net increase in cash and cash equivalents
        		  -2,726,825 
          cash and cash equivalents, beginning of period
        		  11,247,403 
          cash and cash equivalents, end of the period
        		  8,520,578 
          supplemental disclosure of noncash investing and financing activities:
        		   
          offering costs included in accounts payable